{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:51:17Z","timestamp":1791424277094,"version":"4.3.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,10,30]],"date-time":"2002-10-30T00:00:00Z","timestamp":1035936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1038\/sj.npp.1300101","type":"journal-article","created":{"date-parts":[[2003,3,24]],"date-time":"2003-03-24T16:52:12Z","timestamp":1048524732000},"page":"755-764","source":"Crossref","is-referenced-by-count":80,"title":["A Clinical Laboratory Paradigm for Evaluating Medication Effects on Alcohol Consumption: Naltrexone and Nalmefene"],"prefix":"10.1038","volume":"28","author":[{"given":"David J","family":"Drobes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Voronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,10,30]]},"reference":[{"key":"BF1300101_CR1","unstructured":"American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC."},{"key":"BF1300101_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archpsyc.1977.01770220111013","volume":"34","author":"NC Andreasen","year":"1977","unstructured":"Andreasen NC, Endicott J, Spitzer RL, Winokur G (1977). The family history method using diagnostic criteria. Arch Gen Psychiatry 34: 1229–1235.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300101_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1530-0277.1995.tb01475.x","volume":"19","author":"RF Anton","year":"1995","unstructured":"Anton RF, Moak DH, Latham P (1995). The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19: 92–99.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR4","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"RF Anton","year":"1999","unstructured":"Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758–1764.","journal-title":"Am J Psychiatry"},{"key":"BF1300101_CR5","volume-title":"Depression: Clinical, Experimental, and Theoretical Aspects","author":"AT Beck","year":"1967","unstructured":"Beck AT (1967). Depression: Clinical, Experimental, and Theoretical Aspects. Hoeber: New York."},{"key":"BF1300101_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893–897.","journal-title":"J Consult Clin Psychol"},{"key":"BF1300101_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R et al (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35: 587–593.","journal-title":"Alcohol Alcohol"},{"key":"BF1300101_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/0024-3205(95)00057-D","volume":"56","author":"JA Culpepper-Morgan","year":"1995","unstructured":"Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ (1995). Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 56: 1187–1192.","journal-title":"Life Sci"},{"key":"BF1300101_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1530-0277.1999.tb04099.x","volume":"23","author":"D Davidson","year":"1999","unstructured":"Davidson D, Palfai T, Bird C, Swift R (1999). Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23: 195–203.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1530-0277.1996.tb01679.x","volume":"20","author":"D Davidson","year":"1996","unstructured":"Davidson D, Swift R, Fitz E (1996). Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20: 732–739.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1530-0277.1987.tb01306.x","volume":"11","author":"LJ Davis","year":"1987","unstructured":"Davis LJ, Hurt RD, Morse RM, O'Brien PC (1987). Discriminant analysis of the Self-Administered Alcoholism Screening Test. Alcohol Clin Exp Res 11: 269–273.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0091-3057(90)90019-E","volume":"37","author":"DL De Haven-Hudkins","year":"1990","unstructured":"De Haven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV et al (1990). Pharmacologic profile of NPC168 (naltrexonephenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37: 497–504.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300101_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s002130051085","volume":"146","author":"H de Wit","year":"1999","unstructured":"de Wit H, Svenson J, York A (1999). Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology 146: 33–41.","journal-title":"Psychopharmacology"},{"key":"BF1300101_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.15288\/jsa.2000.61.220","volume":"61","author":"DJ Drobes","year":"2000","unstructured":"Drobes DJ, Anton RF (2000). Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol 61: 220–224.","journal-title":"J Stud Alcohol"},{"key":"BF1300101_CR15","first-page":"1630","volume":"271","author":"PJ Emmerson","year":"1994","unstructured":"Emmerson PJ, Liu M, Woods JH, Medzihradsky F (1994). Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J Pharmacol Exp Therap 271: 1630–1637.","journal-title":"J Pharmacol Exp Therap"},{"key":"BF1300101_CR16","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW (1994). Structured clinical interview for axis I DSM-IV disorders—patient edition (SCID-I\/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute."},{"key":"BF1300101_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJM199001113220205","volume":"322","author":"M Frezza","year":"1990","unstructured":"Frezza M, Di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS (1990). High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322: 95–99.","journal-title":"N Engl J Med"},{"key":"BF1300101_CR18","first-page":"284","volume":"287","author":"JC Froehlich","year":"1998","unstructured":"Froehlich JC, Badia-Elder NE, Zink RW, McCullough DE, Portoghese PS (1998). Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. J Pharmacol Exp Ther 287: 284–292.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300101_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0091-3057(90)90174-G","volume":"35","author":"JC Froehlich","year":"1990","unstructured":"Froehlich JC, Harts J, Lumeng L, Li TK (1990). Naloxone attenuates voluntary alcohol intake in rats selectively bred for high alcohol preference. Pharmacol Biochem Behav 35: 385–390.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300101_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1530-0277.2002.tb02599.x","volume":"26","author":"MA Goldman","year":"2002","unstructured":"Goldman MA (2002). Expectancy and risk for alcoholism: the unfortunate exploitation of a fundamental characteristic of neurobehavioral adaptation. Alcohol Clin Exp Res 26: 737–746.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0091-3057(96)00446-7","volume":"57","author":"ST Higgins","year":"1997","unstructured":"Higgins ST (1997). The influence of alternative reinforcers on cocaine use and abuse: a brief review. Pharmacol Biochem Behav 57: 419–427.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1300101_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s002130050156","volume":"129","author":"AC King","year":"1997","unstructured":"King AC, Volpicelli JR, Frazer A, O'Brien CP (1997a). Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129: 15–22.","journal-title":"Psychopharmacology"},{"key":"BF1300101_CR23","first-page":"906","volume":"21","author":"AC King","year":"1997","unstructured":"King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997b). Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21: 906–909.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","volume":"25","author":"HR Kranzler","year":"2001","unstructured":"Kranzler HR, Van Kirk J (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR25","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa011127","volume":"345","author":"JH Krystal","year":"2001","unstructured":"Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001). Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734–1739.","journal-title":"N Engl J Med"},{"key":"BF1300101_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/07853899409148346","volume":"26","author":"CS Lieber","year":"1994","unstructured":"Lieber CS (1994). Hepatic and metabolic effects of ethanol: pathogenesis and prevention. Ann Med 26: 325–330.","journal-title":"Ann Med"},{"issue":"Suppl","key":"BF1300101_CR27","first-page":"163","volume":"2","author":"CS Lieber","year":"1994","unstructured":"Lieber CS, Gentry RT, Baraona E (1994). First pass metabolism of ethanol. Alcohol Alcohol 2(Suppl): 163–169.","journal-title":"Alcohol Alcohol"},{"key":"BF1300101_CR28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","volume":"18","author":"BJ Mason","year":"1994","unstructured":"Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B et al (1994). A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol Clin Exp Res 18: 1162–1167.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","volume":"56","author":"BJ Mason","year":"1999","unstructured":"Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999). A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56: 719–724.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300101_CR30","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1530-0277.2000.tb02107.x","volume":"24","author":"ME McCaul","year":"2000","unstructured":"McCaul ME, Wand GS, Rohde C, Lee SM (2000). Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res 24: 1385–1391.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s002130000479","volume":"151","author":"LD Middaugh","year":"2000","unstructured":"Middaugh LD, Bandy AE (2000). Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL\/6 mice. Psychopharmacology 151: 321–327.","journal-title":"Psychopharmacology"},{"key":"BF1300101_CR32","volume-title":"Motivational Interviewing: Preparing People to Change Addictive Behavior","author":"WR Miller","year":"1991","unstructured":"Miller WR, Rollnick S (1991). Motivational Interviewing: Preparing People to Change Addictive Behavior. Guilford Press: New York."},{"key":"BF1300101_CR33","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1021\/jm00072a002","volume":"36","author":"CH Mitch","year":"1993","unstructured":"Mitch CH, Leander JD, Mendelsohn LG, Shaw WN, Wong DT, Cantrell BE et al (1993). 3,4-dimethyl-4-(3-hydroxyphenyl) piperidines: opioid antagonists with potent anorectant activity. J Med Chem 36: 2842–2850.","journal-title":"J Med Chem"},{"key":"BF1300101_CR34","unstructured":"National Advisory Council on Alcohol Abuse and Alcoholism (1988). Recommended council guidelines on ethyl alcohol administration in human experimentation. US DHHS, ADAMHA: Rockville, MD."},{"key":"BF1300101_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3928\/0048-5713-19951101-11","volume":"25","author":"S O'Malley","year":"1995","unstructured":"O'Malley S, Croop R, Wroblewski J, Labriola D, Volpicelli J (1995). Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Ann 25: 11–25.","journal-title":"Psychiatric Ann"},{"key":"BF1300101_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O'Malley","year":"1992","unstructured":"O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 881–887.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300101_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002130100919","volume":"160","author":"SS O'Malley","year":"2002","unstructured":"O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamic–pituitary–adrenocortical axis. Psychopharmacology 160: 19–29.","journal-title":"Psychopharmacology"},{"key":"BF1300101_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1037\/1064-1297.7.3.266","volume":"7","author":"T Palfai","year":"1999","unstructured":"Palfai T, Davidson D, Swift R (1999). Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies. Exp Clin Psychopharmacol 7: 266–273.","journal-title":"Exp Clin Psychopharmacol"},{"key":"BF1300101_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00008877-200107000-00006","volume":"12","author":"TA Shahan","year":"2001","unstructured":"Shahan TA, Bickel WK, Badger GJ, Giordano LA (2001). Sensitivity of nicotine-containing and de-nicotinized cigarette consumption to alternative non-drug reinforcement: a behavioral economic analysis. Behav Pharmacol 12: 277–284.","journal-title":"Behav Pharmacol"},{"key":"BF1300101_CR40","unstructured":"Singleton EG, Tiffany ST, Henningfield JE (1999). Alcohol craving questionnaire (ACQ-NOW): background, scoring, and administration (Revised). Intramural Research Program NIDA: Baltimore, MD."},{"key":"BF1300101_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","volume":"91","author":"HA Skinner","year":"1982","unstructured":"Skinner HA, Allen BA (1982). Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91: 199–209.","journal-title":"J Abnorm Psychol"},{"key":"BF1300101_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biological Methods","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen J, Litten RZ (eds). Measuring Alcohol Consumption: Psychosocial and Biological Methods. Humana Press: Totowa, NJ. pp 41–72."},{"key":"BF1300101_CR43","unstructured":"Sobell MB, Sobell LC (1993). Problem drinkers: guided self-change treatment. Guilford Press: New York."},{"issue":"Suppl","key":"BF1300101_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.15288\/jsas.1994.s12.70","volume":"12","author":"RL Stout","year":"1994","unstructured":"Stout RL, Wirtz PW, Carbonari JP, Del Boca FK (1994). Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol 12(Suppl): 70–75.","journal-title":"J Stud Alcohol"},{"key":"BF1300101_CR45","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1530-0277.1998.tb05932.x","volume":"22","author":"MF Stromberg","year":"1998","unstructured":"Stromberg MF, Volpicelli JR, O'Brien CP (1998). Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat. Alcohol Clin Exp Res 22: 2186–2191.","journal-title":"Alcohol Clin Exp Res"},{"key":"BF1300101_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0899-3289(88)80021-X","volume":"1","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Naranjo CA, Sellers EM (1989a). Compliance among heavy alcohol users in clinical drug trials. J Subst Abuse 1: 183–194.","journal-title":"J Subst Abuse"},{"key":"BF1300101_CR47","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989b). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment of alcohol scale (CIWA-ar). Br J Addict 84: 1353–1357.","journal-title":"Br J Addict"},{"key":"BF1300101_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1176\/ajp.151.10.1463","volume":"151","author":"RM Swift","year":"1994","unstructured":"Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994). Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151: 1463–1467.","journal-title":"Am J Psychiatry"},{"key":"BF1300101_CR49","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300101_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","volume":"54","author":"JR Volpicelli","year":"1997","unstructured":"Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997). Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54: 737–742.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300101_CR51","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1046\/j.1471-4159.2001.00362.x","volume":"77","author":"D Wang","year":"2001","unstructured":"Wang D, Raehal KM, Bilsky EJ, Sadee W (2001). Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77: 1590–1600.","journal-title":"J Neurochem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:27:11Z","timestamp":1704810431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,30]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["BF1300101"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300101","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,30]]}}}